Skip to main content

Advertisement

SpringerLink
Log in

Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The present study is to investigate whether extranodal (EN) metabolic tumor volume (MTV) would have a specific clinical meaning for survival in EN diffuse large B cell lymphoma (DLBCL) patients. Two hundred forty DLBCL patients with EN involvement received 18F-fluorodeoxygenase (FDG) positron emission tomography/computed tomography (PET/CT) were enrolled. Survival analysis revealed that low EN MTV (PFS [progression-free survival], HR = 0.278, 95% CI = 0.127–0.807, p = 0.001; OS [overall survival], HR = 0.320, 95% CI = 0.145–0.703, p = 0.003), low total MTV (PFS, HR = 0.194, 95% CI = 0.085–0.445, p < 0.001; OS, HR = 0.213, 95% CI = 0.092–0.491, p < 0.007), and high National Cancer Center Network-International Prognostic Index score (PFS, HR = 3.152, 95% CI = 1.732–5.734, p < 0.001; OS, HR = 2.457, 95% CI = 1.363–4.430, p = 0.003) were independently associated with survivals in the patients. Our data showed that EN MTV is a useful and novel prognostic parameter for predicting survival in DLBCL patients with EN involvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3.

Similar content being viewed by others

References

  1. Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16:2780–2795

    Article  CAS  Google Scholar 

  2. De Paepe P, De Wolf-Peeters C (2007) Diffuse large B cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia. 21:37–43

    Article  Google Scholar 

  3. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM (2008) Stromal gene signatures in large-B cell lymphomas. N Engl J Med 359:2313–2323

    Article  CAS  Google Scholar 

  4. Dawson IM, Cornes JS, Morson BC (1961) Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg 49:80–89

    Article  CAS  Google Scholar 

  5. Lewin KJ, Ranchod M, Dorfman RF (1978) Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer. 42:693–707

    Article  CAS  Google Scholar 

  6. Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L (1980) Gastrointestinal involvement in non-Hodgkin’s lymphoma. Cancer. 46:215–222

    Article  CAS  Google Scholar 

  7. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 123:837–842

    Article  CAS  Google Scholar 

  8. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048–3058

    Article  Google Scholar 

  9. Miyazaki Y, Nawa Y, Miyagawa M, Kohashi S, Nakase K, Yasukawa M, Hara M (2013) Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma. Ann Hematol 92:239–244

    Article  CAS  Google Scholar 

  10. Huang H, Xiao F, Han X, Zhong L, Zhong H, Xu L, Zhu J, Ni B, Liu J, Fang Y, Zhang M, Shen L, Wang T, Liu J, Shi Y, Chen Y, Zheng L, Liu Q, Chen F, Wang J (2016) Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B cell lymphoma. Nucl Med Commun 37:689–698

    Article  CAS  Google Scholar 

  11. Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, Lee GW, Kim SJ, Lee SM, Chung DS (2012) Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 91:697–703

    Article  CAS  Google Scholar 

  12. Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, Gotti M et al (2015) Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B cell lymphoma. Blood. 126:950–956

    Article  CAS  Google Scholar 

  13. Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, Chong A, Moon JH, Kim JH, Lee SM, Kim SJ, Shin HJ (2013) Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma. Cancer Sci 104:1656–1661

    Article  CAS  Google Scholar 

  14. Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, Toubeau M, Ferrant E, Brunotte F, Casasnovas RO (2014) Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41:1735–1743

    Article  Google Scholar 

  15. Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, Gallamini A, Siegel BA, Cashen AF, Véra P, Tilly H, Versari A, Itti E (2014) Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging 41:2017–2022

    Article  CAS  Google Scholar 

  16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586

    Article  Google Scholar 

  17. Song MK, Chung JS, Shin HJ, Moon JH, Lee JO, Lee HS, Lee SM, Lee GW, Lee SE, Kim SJ (2012) Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci 103:477–482

    Article  CAS  Google Scholar 

  18. Møller MB, Pedersen NT, Christensen BE (2004) Diffuse large B cell lymphoma: clinical implications of extranodal versus nodal presentation - a population-based study of 1575 cases. Br J Haematol 124:151–159

    Article  Google Scholar 

  19. El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D et al (2015) Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B cell lymphoma. Am J Hematol 90:1041–1046

    Article  CAS  Google Scholar 

  20. Castillo JJ, Winer ES, Olszewski AJ (2014) Sites of extranodal involvement are prognostic in patients with diffuse large B cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol 89:310–314

    Article  CAS  Google Scholar 

  21. Montalbán C, Díaz-López A, Dlouhy I, Rovira J, Lopez-Guillermo A, Alonso S, Martín A, Sancho JM, García O, Sánchez JM, Rodríguez M, Novelli S, Salar A, Gutiérrez A, Rodríguez-Salazar MJ, Bastos M, Domínguez JF, Fernández R, Gonzalez de Villambrosia S, Queizan JA, Córdoba R, de Oña R, López-Hernandez A, Freue JM, Garrote H, López L, Martin-Moreno AM, Rodriguez J, Abraira V, García JF, the GELTAMO-IPI Project Investigators (2017) Validation of the NCCN-IPI for diffuse large B cell lymphoma (DLBCL): the addition of β2 -microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol 176:918–928

    Article  Google Scholar 

  22. Hui D, Proctor B, Donaldson J, Shenkier T, Hoskins P, Klasa R et al (2010) Prognostic implications of extranodal involvement in patients with diffuse large B cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma 51:1658–1667

    Article  CAS  Google Scholar 

  23. Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, Hashimoto C, Tamura K, Sato K, Ishigatsubo Y (2012) Prognostic impact of extranodal involvement in diffuse large B cell lymphoma in the rituximab era. Cancer. 118:4166–4172

    Article  Google Scholar 

  24. Yoo C, Kim S, Sohn BS, Kim JE, Yoon DH, Huh J, Lee DH, Kim SW, Lee JS, Suh C (2010) Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B cell lymphoma. Korean J Intern Med 25:301–308

    Article  Google Scholar 

  25. El-Galaly TC, Villa D, Michaelsen TY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH et al (2017) The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer 75:195–203

    Article  Google Scholar 

  26. Lee DY, Kang K, Jung H, Park YM, Cho JG, Baek SK, Kwon SY, Jung KY, Woo JS (2019) Extranodal involvement of diffuse large B cell lymphoma in the head and neck: An indicator of good prognosis. Auris Nasus Larynx 46:114–121

    Article  Google Scholar 

  27. Son SH, Jeong SY, Jung JH, Kim CY, Kim DH, Lee SW et al (2015) Prognostic implications of metabolic tumor volume on 18F-FDG PET/CT in diffuse large B cell lymphoma patients with extranodal involvement. J Nucl Med 56(supplement 3):1353

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Hanyang University Hanmaeum Changwon Hospital, Changwon, Korea

    Moo-Kon Song

  2. Department of Hematology-Oncology, School of Medicine, Pusan National University Hospital Medical Research Institute, 1-10 Ami-dong, Seo-gu, Busan, 602-739, Republic of Korea

    Joo-Seop Chung

  3. Department of Hematology, Busan Haeundae Paik Hospital, Busan, Korea

    Sung-Nam Lim

  4. Department of Hematology, Busan Paik Hospital, Busan, Korea

    Won-Sik Lee & Sang-Min Lee

  5. Department of Nuclear Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea

    Seong-Jang Kim

  6. Department of Nuclear Medicine, Busan Haeundae Paik Hospital, Busan, Korea

    Hye-Kyung Shim

  7. Department of Nuclear Medicine, Busan Paik Hospital, Busan, Korea

    Seok-Mo Lee

Authors
  1. Moo-Kon Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joo-Seop Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sung-Nam Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Won-Sik Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sang-Min Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seong-Jang Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hye-Kyung Shim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seok-Mo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joo-Seop Chung.

Ethics declarations

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors

Conflict of interest

The authors have no conflict of interest to declare.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Song, MK., Chung, JS., Lim, SN. et al. Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement. Ann Hematol 100, 1221–1229 (2021). https://doi.org/10.1007/s00277-021-04498-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04498-9

Keywords

Search

Navigation